Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.32
IDXX's Cash to Debt is ranked lower than
80% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. IDXX: 0.32 )
Ranked among companies with meaningful Cash to Debt only.
IDXX' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 8.45 Max: No Debt
Current: 0.32
Equity to Asset -0.01
IDXX's Equity to Asset is ranked lower than
92% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. IDXX: -0.01 )
Ranked among companies with meaningful Equity to Asset only.
IDXX' s Equity to Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.74 Max: 0.87
Current: -0.01
-0.06
0.87
Interest Coverage 9.84
IDXX's Interest Coverage is ranked lower than
72% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 96.50 vs. IDXX: 9.84 )
Ranked among companies with meaningful Interest Coverage only.
IDXX' s Interest Coverage Range Over the Past 10 Years
Min: 9.84  Med: 58.07 Max: 276.91
Current: 9.84
9.84
276.91
F-Score: 5
Z-Score: 6.20
M-Score: -2.69
WACC vs ROIC
4.07%
28.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.74
IDXX's Operating margin (%) is ranked higher than
85% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. IDXX: 18.74 )
Ranked among companies with meaningful Operating margin (%) only.
IDXX' s Operating margin (%) Range Over the Past 10 Years
Min: 14.76  Med: 18 Max: 20.3
Current: 18.74
14.76
20.3
Net-margin (%) 11.94
IDXX's Net-margin (%) is ranked higher than
82% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.52 vs. IDXX: 11.94 )
Ranked among companies with meaningful Net-margin (%) only.
IDXX' s Net-margin (%) Range Over the Past 10 Years
Min: 10.19  Med: 12.46 Max: 13.78
Current: 11.94
10.19
13.78
ROA (%) 13.64
IDXX's ROA (%) is ranked higher than
93% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. IDXX: 13.64 )
Ranked among companies with meaningful ROA (%) only.
IDXX' s ROA (%) Range Over the Past 10 Years
Min: 13.44  Med: 15.96 Max: 17.84
Current: 13.64
13.44
17.84
ROC (Joel Greenblatt) (%) 60.02
IDXX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. IDXX: 60.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IDXX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 53.83  Med: 62.77 Max: 85.38
Current: 60.02
53.83
85.38
Revenue Growth (3Y)(%) 14.10
IDXX's Revenue Growth (3Y)(%) is ranked higher than
77% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. IDXX: 14.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IDXX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.4  Med: 11.2 Max: 23.1
Current: 14.1
8.4
23.1
EBITDA Growth (3Y)(%) 12.00
IDXX's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. IDXX: 12.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IDXX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.3  Med: 15.1 Max: 96.9
Current: 12
3.3
96.9
EPS Growth (3Y)(%) 9.00
IDXX's EPS Growth (3Y)(%) is ranked higher than
69% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. IDXX: 9.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IDXX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.5  Med: 16 Max: 26.1
Current: 9
-0.5
26.1
» IDXX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

IDXX Guru Trades in Q3 2015

Ray Dalio 7,826 sh (+85.19%)
RS Investment Management 370,574 sh (+12.62%)
Chuck Royce 1,770,922 sh (+9.54%)
Ruane Cunniff 8,167,274 sh (+1.04%)
Mairs and Power 3,998 sh (unchged)
Jeremy Grantham Sold Out
Paul Tudor Jones 10,711 sh (-0.18%)
Ron Baron 7,061,667 sh (-1.53%)
Chris Davis 623,573 sh (-15.00%)
George Soros 6,800 sh (-62.17%)
Jim Simons 33,100 sh (-87.01%)
» More
Q4 2015

IDXX Guru Trades in Q4 2015

Jim Simons 127,700 sh (+285.80%)
Mairs and Power 3,998 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
Ray Dalio Sold Out
George Soros Sold Out
Ruane Cunniff 8,027,368 sh (-1.71%)
Ron Baron 6,891,469 sh (-2.41%)
Chuck Royce 1,207,722 sh (-31.80%)
Chris Davis 264,392 sh (-57.60%)
» More
Q1 2016

IDXX Guru Trades in Q1 2016

Columbia Wanger 1,049,000 sh (New)
Jim Simons 437,504 sh (+242.60%)
Mairs and Power 3,998 sh (unchged)
Chris Davis Sold Out
Ron Baron 6,603,503 sh (-4.18%)
Ruane Cunniff 7,668,176 sh (-4.47%)
Chuck Royce 882,612 sh (-26.92%)
» More
Q2 2016

IDXX Guru Trades in Q2 2016

Paul Tudor Jones 5,712 sh (New)
Jim Simons 537,404 sh (+22.83%)
Mairs and Power 3,998 sh (unchged)
Ron Baron 6,584,973 sh (-0.28%)
Chuck Royce 863,812 sh (-2.13%)
Columbia Wanger 370,439 sh (-64.69%)
Ruane Cunniff 107,894 sh (-98.59%)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:Q, NYSE:DGX, NAS:DXCM, OTCPK:ERFSF, OTCPK:SSMXY, NAS:QGEN, NYSE:PKI, NYSE:LH, OTCPK:BMXMF, NYSE:BIO, NYSE:A, NAS:ICLR, NYSE:CRL, NAS:VWR, NAS:PRXL, NAS:BRKR, OTCPK:DSRLF, NYSE:ALR, NAS:PRAH, OTCPK:SWTUY » details
Traded in other countries:IX1.Germany,
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for the veterinary, bioresearch, water, livestock, poultry and dairy markets.

IDEXX Laboratories Inc was incorporated in 1983. The Company develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. It also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its products and services are: Point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assays; Veterinary reference laboratory diagnostic and consulting services; Practice management systems and services and diagnostic imaging systems used by veterinarians; Biological materials testing, laboratory animal diagnostic instruments and services used by the biomedical research community; Diagnostic, health-monitoring and food safety testing products for livestock, poultry and dairy; Products that test water for certain microbiological contaminants; Point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market. The Company operates through three business segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG); water quality products (Water); and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and food, which it refers to as Livestock, Poultry and Dairy (LPD). Its other operating segment combines and presents products for the human point-of-care medical diagnostics market (OPTI Medical) with its pharmaceutical product line and its out-licensing arrangements. CAG provides to veterinarian's diagnostic capabilities and information management solutions that enhance the health and well-being of pets. The breadth and complementary nature of its products and services comprise a competitive advantage that it refers to as the IDEXX Diagnostic Advantage, providing veterinarians with the tools and services to offer veterinary medical care. The CAG Diagnostics provides diagnostic capabilities that meet veterinarians' diverse needs through a variety of modalities, including in-clinic diagnostic solutions and outside reference laboratory services. Regardless of modality utilized, veterinarians are provided with clinically relevant data which is integrated within its information management technologies. The result is a comprehensive view of patient diagnostic information that is easily accessible by both the veterinarian and pet owner. The water segment provides testing solutions for easy, rapid and accurate detection and quantification of various microbiological parameters in water, helping to ensure water safety for billions of people around the world. Its products are the Colilert, Colilert-18 and Colisure tests, which simultaneously detect the presence of total coliforms and E. coli in water. These organisms are used as microbial indicators for potential fecal

Guru Investment Theses on IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories - Aug 17, 2016

IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading company in veterinary diagnostics, rallied in the second quarter after reporting strong financial results. Organic revenue growth was up 11%, driven by instrument revenue gains of 16% (and new placements up 25%), consumables’ sales up 12%, and reference labs sales up 15%. The company’s efforts to build a direct sales force and introduce new innovative products are showing terrific results. We expect revenue growth to accelerate as additional tests gain traction and the productivity of the new salesforce continues to improve. The company remained aggressive with its share repurchase program. We applaud the company’s plan to take on some leverage to buy in shares, especially as they bought at the lows, and since we believe the business is so stable and annuity-like that the balance sheet should have a reasonable amount of debt to optimize equity returns for the shareholders.





From Baron Funds' Small Cap Fund second quarter 2016 shareholder letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jul 25, 2016

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported another quarter of strong financial results. We continue to believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 25% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories continued to grow at more than twice the rate of its main competitor. We believe that these trends, coupled with the revenue contributions from its new proprietary tests, has potential for better revenue and earnings growth during the next few years.



Baron Asset Fund second quarter shareholder letter.



Check out Ron Baron latest stock trades

Ruane Cunniff Comments on Idexx Laboratories - Jul 13, 2016

We made the difficult decision during the quarter to part with our longtime holding in Idexx Laboratories (NASDAQ:IDXX). Idexx had been a wonderful stock for us over the past 13 years, compounding at better than a 17% rate from the time of our original purchases in 2003 through June 30. This compares to a 7.4% compound for the S&P 500 Index over the same period. Idexx has a terrific market position in veterinary diagnostics and a very capable CEO in Jon Ayers. But the market fully realizes Idexx’s strengths. It is according Idexx a price-to- earnings ratio of more than 40x the 2016 consensus earnings per share estimate of $ 2.21. The company has grown earnings per share at an 11% rate for the past five years and should grow a bit below that rate in 2016. The market helped with our decision as the price of Idexx shares rose sharply during the quarter. We owe a huge debt of gratitude to Jon Ayers. He is a hero to Sequoia shareholders and greatly respected by all of us.



From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund second quarter 2016 shareholder letter.

Check out Ruane Cunniff latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Apr 26, 2016

Shares IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported healthy financial results. We believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 50% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories grew at more than twice the rate of its main competitor. We also observed rising productivity of its field salesforce, and a rebound in its rapid assay products. We believe that these trends, coupled with a number of new tests that should emerge from its meaningful research and development effort, will drive increased organic revenue and earnings growth during the next few years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jan 14, 2016

Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a leader in veterinary diagnostics. The company is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. It has had much success placing its proprietary testing instrument in clinics, and has a deep pipeline of tests and products. Its razor/razorblade model results in high retention rates and incremental margins. IDEXX is transitioning to all-direct distribution, which we expect will further enhance margins and future growth.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Nov 04, 2015

Shares of veterinary diagnostics manufacturer IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to the third quarter performance. The company reported strong second quarter results that demonstrated share gains in instruments and reference labs, and assuaged concerns regarding its competitive position in rapid assays. Catalyst placements grew 44% in the quarter, driven by the launch of CatalystOne in the U.S. and Europe. Premium hematology placements grew 30% in the third quarter, a meaningful increase from 14% in the second quarter. Reference lab results were also strong, growing 12.1% in the third quarter. (Neal Rosenberg)



From Baron Funds' Baron Partners Fund shareholder letter for Q3 2015.



Check out Ron Baron latest stock trades

Sequoia Fund Comments on Idexx - Aug 28, 2015

Arman Kline:



The company had a wonderful 2014. It made a big decision to go to direct distribution. Historically, Idexx (NASDAQ:IDXX) distributed the consumables for its instruments and its rapid assay tests for companion animals through a network of distributors in the US. Overseas it was a little bit more direct. It made a decision to go direct here, and the reason it made that decision is that it felt as the market leader with a dominant market share introducing new technology, new products, it needed a sales force that could encourage the adoption of those products more than it needed the help of distributors to penetrate the market. We think that management made the right decision.



Earlier this year, you may have noticed in the first quarter, Idexx had a little bit of a hiccup as a result of that move to direct distribution. A competitor came out with a lower priced product and distributors picked it up because Idexx was no longer selling through them. The competitor was very aggressive, and, as the CEO of Idexx said, there is now a rapid assay price war going on in the industry. The business is still growing very nicely, but the stock was priced for perfection — last year it was trading for a high 30s multiple of forward earnings. Most of you have probably noticed we have sold down our position as a result of that valuation. We are still large shareholders. We still believe in the business. We think it is unique. We think it has a long runway. We think it will continue to dominate that space. We remain excited about the future there and believe in its direct distribution model. Do you want to add anything, Greg?



Greg Steinmetz:



Idexx is responsible for at least 75% if not more of all of the R&D spending in veterinary diagnostics. It can earn a nice return on that because this megatrend of the humanization of pets is showing no signs of stopping. People will spend anything on their animal if the veterinarian gives them a credible reason why they should. And it is a lot more than just rich people. It is a broad swath of pet owners. Idexx, to its credit, is a great believer in veterinary diagnostics. Management sees it as a very long-lived opportunity. It has really been paying off. Despite the issue with rapid assay this year, we are still going to get 10% organic growth. International is going gangbusters, and there the humanization of pets is just getting started. Even in China — where they are boiling Tibetan mastiffs, if you read the story in the Times two weeks ago — people are starting to treat animals more like humans. It is an opportunity that Idexx is going to benefit a great deal from.



From Ruane, Cunniff & Goldfarb Investor Day 2015 Transcript Part II - Sequoia Fund.



Check out Ruane Cunniff latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Aug 18, 2015

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), a leader in veterinary diagnostics, detracted from performance after outperforming meaningfully during recent periods. We attribute a portion of the stock’s decline to greater-than-expected foreign exchange headwinds. Separately, the company noted increased competition and lower prices in a sub-segment of its product portfolio, which we estimate accounts for just 3% of total revenue. We believe this enhanced competition stems from the company’s recent transition to a direct sales strategy in the U.S., and we are optimistic that management will successfully react with pricing programs to better serve these customers in the future. We expect accelerating organic revenue growth over the next several years, driven by productivity benefits from its new domestic sales strategy, additional products, and ongoing success in international markets. We believe that faster top line growth should lead to accelerated margin expansion, creating a virtuous cycle of earnings growth, reinvestment, and returns of capital to shareholders.



From Baron Funds' second quarter commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc - Mar 23, 2015

Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose in the fourth quarter on better-than-expected earnings and progress on moving to a direct distribution model in the U.S. IDEXX’s fundamentals continue to improve, with organic growth in its core business reaching 12% in the most recently reported quarter. We believe organic revenue growth at current levels is sustainable due to recent innovations in IDEXX’s portfolio of diagnostic products, instruments, data management tools, and geographic expansion. (Rebecca Ellin)

From Ron Baron (Trades, Portfolio)'s Baron Partners Fund Fourth Quarter 2014 Commentary.

Check out Ron Baron latest stock trades

Top Ranked Articles about IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories Guru stock highlight
IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading company in veterinary diagnostics, rallied in the second quarter after reporting strong financial results. Organic revenue growth was up 11%, driven by instrument revenue gains of 16% (and new placements up 25%), consumables’ sales up 12%, and reference labs sales up 15%. The company’s efforts to build a direct sales force and introduce new innovative products are showing terrific results. We expect revenue growth to accelerate as additional tests gain traction and the productivity of the new salesforce continues to improve. The company remained aggressive with its share repurchase program. We applaud the company’s plan to take on some leverage to buy in shares, especially as they bought at the lows, and since we believe the business is so stable and annuity-like that the balance sheet should have a reasonable amount of debt to optimize equity returns for the shareholders. Read more...
Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported another quarter of strong financial results. We continue to believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 25% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories continued to grow at more than twice the rate of its main competitor. We believe that these trends, coupled with the revenue contributions from its new proprietary tests, has potential for better revenue and earnings growth during the next few years. Read more...
Ruane Cunniff Comments on Idexx Laboratories Guru stock highlight
We made the difficult decision during the quarter to part with our longtime holding in Idexx Laboratories (NASDAQ:IDXX). Idexx had been a wonderful stock for us over the past 13 years, compounding at better than a 17% rate from the time of our original purchases in 2003 through June 30. This compares to a 7.4% compound for the S&P 500 Index over the same period. Idexx has a terrific market position in veterinary diagnostics and a very capable CEO in Jon Ayers. But the market fully realizes Idexx’s strengths. It is according Idexx a price-to- earnings ratio of more than 40x the 2016 consensus earnings per share estimate of $ 2.21. The company has grown earnings per share at an 11% rate for the past five years and should grow a bit below that rate in 2016. The market helped with our decision as the price of Idexx shares rose sharply during the quarter. We owe a huge debt of gratitude to Jon Ayers. He is a hero to Sequoia shareholders and greatly respected by all of us. Read more...
Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Shares IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported healthy financial results. We believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 50% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories grew at more than twice the rate of its main competitor. We also observed rising productivity of its field salesforce, and a rebound in its rapid assay products. We believe that these trends, coupled with a number of new tests that should emerge from its meaningful research and development effort, will drive increased organic revenue and earnings growth during the next few years. Read more...
Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a leader in veterinary diagnostics. The company is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. It has had much success placing its proprietary testing instrument in clinics, and has a deep pipeline of tests and products. Its razor/razorblade model results in high retention rates and incremental margins. IDEXX is transitioning to all-direct distribution, which we expect will further enhance margins and future growth. Read more...
Baron Funds Comments on IDEXX Laboratories Guru stock highlight.
Shares of veterinary diagnostics manufacturer IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to the third quarter performance. The company reported strong second quarter results that demonstrated share gains in instruments and reference labs, and assuaged concerns regarding its competitive position in rapid assays. Catalyst placements grew 44% in the quarter, driven by the launch of CatalystOne in the U.S. and Europe. Premium hematology placements grew 30% in the third quarter, a meaningful increase from 14% in the second quarter. Reference lab results were also strong, growing 12.1% in the third quarter. (Neal Rosenberg) Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 50.90
IDXX's P/E(ttm) is ranked lower than
76% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.71 vs. IDXX: 50.90 )
Ranked among companies with meaningful P/E(ttm) only.
IDXX' s P/E(ttm) Range Over the Past 10 Years
Min: 15.18  Med: 30.82 Max: 50.62
Current: 50.9
15.18
50.62
Forward P/E 46.73
IDXX's Forward P/E is ranked lower than
89% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.01 vs. IDXX: 46.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 50.90
IDXX's PE(NRI) is ranked lower than
76% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.41 vs. IDXX: 50.90 )
Ranked among companies with meaningful PE(NRI) only.
IDXX' s PE(NRI) Range Over the Past 10 Years
Min: 15.02  Med: 30.64 Max: 50.62
Current: 50.9
15.02
50.62
Price/Owner Earnings (ttm) 51.06
IDXX's Price/Owner Earnings (ttm) is ranked lower than
73% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.37 vs. IDXX: 51.06 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
IDXX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 21.36  Med: 34.16 Max: 73.8
Current: 51.06
21.36
73.8
P/S 6.11
IDXX's P/S is ranked lower than
69% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. IDXX: 6.11 )
Ranked among companies with meaningful P/S only.
IDXX' s P/S Range Over the Past 10 Years
Min: 1.75  Med: 3.97 Max: 6.07
Current: 6.11
1.75
6.07
PFCF 49.10
IDXX's PFCF is ranked lower than
77% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.29 vs. IDXX: 49.10 )
Ranked among companies with meaningful PFCF only.
IDXX' s PFCF Range Over the Past 10 Years
Min: 13.03  Med: 34.04 Max: 93.42
Current: 49.1
13.03
93.42
POCF 36.36
IDXX's POCF is ranked lower than
86% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.28 vs. IDXX: 36.36 )
Ranked among companies with meaningful POCF only.
IDXX' s POCF Range Over the Past 10 Years
Min: 11.44  Med: 24.03 Max: 44.83
Current: 36.36
11.44
44.83
EV-to-EBIT 33.96
IDXX's EV-to-EBIT is ranked lower than
71% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.76 vs. IDXX: 33.96 )
Ranked among companies with meaningful EV-to-EBIT only.
IDXX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.5  Med: 21 Max: 34.6
Current: 33.96
10.5
34.6
EV-to-EBITDA 27.56
IDXX's EV-to-EBITDA is ranked lower than
73% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.60 vs. IDXX: 27.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDXX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.3  Med: 17.2 Max: 28.2
Current: 27.56
8.3
28.2
PEG 4.12
IDXX's PEG is ranked lower than
71% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.76 vs. IDXX: 4.12 )
Ranked among companies with meaningful PEG only.
IDXX' s PEG Range Over the Past 10 Years
Min: 0.77  Med: 2.1 Max: 4.44
Current: 4.12
0.77
4.44
Shiller P/E 75.75
IDXX's Shiller P/E is ranked lower than
83% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.53 vs. IDXX: 75.75 )
Ranked among companies with meaningful Shiller P/E only.
IDXX' s Shiller P/E Range Over the Past 10 Years
Min: 26.11  Med: 50.45 Max: 77.76
Current: 75.75
26.11
77.76
Current Ratio 1.00
IDXX's Current Ratio is ranked lower than
88% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. IDXX: 1.00 )
Ranked among companies with meaningful Current Ratio only.
IDXX' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.46 Max: 6
Current: 1
0.92
6
Quick Ratio 0.78
IDXX's Quick Ratio is ranked lower than
87% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. IDXX: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
IDXX' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.68 Max: 5.14
Current: 0.78
0.71
5.14
Days Inventory 88.85
IDXX's Days Inventory is ranked higher than
51% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 90.15 vs. IDXX: 88.85 )
Ranked among companies with meaningful Days Inventory only.
IDXX' s Days Inventory Range Over the Past 10 Years
Min: 77.45  Med: 82.31 Max: 89.55
Current: 88.85
77.45
89.55
Days Sales Outstanding 45.83
IDXX's Days Sales Outstanding is ranked higher than
72% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. IDXX: 45.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDXX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.43  Med: 40.46 Max: 45.83
Current: 45.83
37.43
45.83
Days Payable 24.05
IDXX's Days Payable is ranked lower than
83% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.91 vs. IDXX: 24.05 )
Ranked among companies with meaningful Days Payable only.
IDXX' s Days Payable Range Over the Past 10 Years
Min: 13.82  Med: 22.5 Max: 27
Current: 24.05
13.82
27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 6.20
IDXX's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.70 vs. IDXX: 6.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IDXX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.4  Med: 2.6 Max: 6.2
Current: 6.2
-1.4
6.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 4.12
IDXX's Price/Projected FCF is ranked lower than
76% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. IDXX: 4.12 )
Ranked among companies with meaningful Price/Projected FCF only.
IDXX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.14  Med: 2.4 Max: 4.12
Current: 4.12
1.14
4.12
Price/DCF (Earnings Based) 2.67
IDXX's Price/DCF (Earnings Based) is ranked lower than
69% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. IDXX: 2.67 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.51
IDXX's Price/Median PS Value is ranked lower than
79% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. IDXX: 1.51 )
Ranked among companies with meaningful Price/Median PS Value only.
IDXX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 0.87 Max: 1.82
Current: 1.51
0.45
1.82
Price/Peter Lynch Fair Value 4.40
IDXX's Price/Peter Lynch Fair Value is ranked lower than
88% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.24 vs. IDXX: 4.40 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
IDXX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.88  Med: 1.8 Max: 4.4
Current: 4.4
0.88
4.4
Earnings Yield (Greenblatt) (%) 2.95
IDXX's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. IDXX: 2.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IDXX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 4.8 Max: 9.5
Current: 2.95
2.9
9.5
Forward Rate of Return (Yacktman) (%) 12.80
IDXX's Forward Rate of Return (Yacktman) (%) is ranked higher than
63% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.46 vs. IDXX: 12.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IDXX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.7  Med: 16.9 Max: 22.4
Current: 12.8
12.7
22.4

More Statistics

Revenue (TTM) (Mil) $1,690
EPS (TTM) $ 2.21
Beta0.36
Short Percentage of Float4.42%
52-Week Range $63.48 - 112.26
Shares Outstanding (Mil)89.53

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,770 1,921 2,090
EPS ($) 2.30 2.67 3.15
EPS w/o NRI ($) 2.30 2.67 3.15
EPS Growth Rate
(3Y to 5Y Estimate)
-0.60%
Dividends Per Share ($)
» More Articles for IDXX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on IDEXX Laboratories Aug 17 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Jul 25 2016 
Baron Asset Fund 2nd Quarter Letter Jul 25 2016 
Ruane Cunniff Comments on Idexx Laboratories Jul 13 2016 
Sequoia Fund Addresses Valeant, New Buys, Board Changes in 2nd Quarter Letter Jul 13 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Apr 26 2016 
Baron Asset Fund 1st Quarter Commentary Apr 26 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Jan 14 2016 
Baron Funds Comments on IDEXX Laboratories Nov 04 2015 
Ron Baron's Largest Purchases During Second Quarter Sep 28 2015 

More From Other Websites
Animal spirits: consumers' devotion lifts pet-care stocks Aug 24 2016
Animal spirits: consumers' devotion lifts pet-care stocks Aug 24 2016
5 Medical Device Stocks to Buy on Q2 Earnings Aug 23 2016
Baron Funds Comments on IDEXX Laboratories Aug 17 2016
IDEXX Investor Day Aug 17 2016
IDEXX Investor Day Aug 17 2016
Canaccord Fireside Chat Takeaways For Abaxis, Heska Aug 16 2016
IDEXX LABORATORIES INC /DE Financials Aug 09 2016
IDEXX Laboratories to Host 2016 Investor Day Aug 08 2016
Pets Are Big Business Now and These Stocks Are Behind the Trend Aug 08 2016
Pets Are Family Now and These Stocks Are Best in Show Aug 08 2016
CMCSA, IDXX, ZTS: Jim Cramer's Views Aug 08 2016
ETF’s with exposure to IDEXX Laboratories, Inc. : August 5, 2016 Aug 05 2016
Idexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $6. ... Aug 05 2016
Has IDEXX Labs Hit an Exhaustion Gap? Aug 04 2016
Cramer: Here's What to Embrace and What to Shun Aug 03 2016
Cramer: Best secular growth story in the world Aug 03 2016
IDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016 Aug 03 2016
IDEXX (IDXX) Tops Q2 Earnings, Revenues, FY16 View Up Aug 03 2016
IDEXX Labs upgraded by Northcoast Aug 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)